nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—hematologic cancer	0.2	1	CbGaD
Scopolamine—ABCB1—Lenalidomide—hematologic cancer	0.0512	0.141	CbGbCtD
Scopolamine—ABCB1—Daunorubicin—hematologic cancer	0.03	0.0826	CbGbCtD
Scopolamine—ABCB1—Alitretinoin—hematologic cancer	0.0294	0.0809	CbGbCtD
Scopolamine—ABCB1—Imatinib—hematologic cancer	0.023	0.0633	CbGbCtD
Scopolamine—ABCB1—Nilotinib—hematologic cancer	0.0209	0.0575	CbGbCtD
Scopolamine—ABCB1—Vinorelbine—hematologic cancer	0.0207	0.057	CbGbCtD
Scopolamine—ABCB1—Dasatinib—hematologic cancer	0.0185	0.0508	CbGbCtD
Scopolamine—ABCB1—Mitoxantrone—hematologic cancer	0.0182	0.0502	CbGbCtD
Scopolamine—ABCB1—Betamethasone—hematologic cancer	0.0162	0.0447	CbGbCtD
Scopolamine—ABCB1—Gemcitabine—hematologic cancer	0.0161	0.0443	CbGbCtD
Scopolamine—ABCB1—Prednisolone—hematologic cancer	0.016	0.0442	CbGbCtD
Scopolamine—ABCB1—Prednisone—hematologic cancer	0.0151	0.0417	CbGbCtD
Scopolamine—ABCB1—Irinotecan—hematologic cancer	0.0144	0.0395	CbGbCtD
Scopolamine—ABCB1—Vinblastine—hematologic cancer	0.0128	0.0351	CbGbCtD
Scopolamine—ABCB1—Vincristine—hematologic cancer	0.0125	0.0345	CbGbCtD
Scopolamine—ABCB1—Cisplatin—hematologic cancer	0.0117	0.0322	CbGbCtD
Scopolamine—ABCB1—Etoposide—hematologic cancer	0.0115	0.0317	CbGbCtD
Scopolamine—ABCB1—Dexamethasone—hematologic cancer	0.00945	0.026	CbGbCtD
Scopolamine—ABCB1—Doxorubicin—hematologic cancer	0.00784	0.0216	CbGbCtD
Scopolamine—ABCB1—Methotrexate—hematologic cancer	0.0076	0.0209	CbGbCtD
Scopolamine—Dizziness—Carmustine—hematologic cancer	0.000101	0.00032	CcSEcCtD
Scopolamine—Pain—Etoposide—hematologic cancer	0.000101	0.00032	CcSEcCtD
Scopolamine—Constipation—Etoposide—hematologic cancer	0.000101	0.00032	CcSEcCtD
Scopolamine—Conjunctivitis—Epirubicin—hematologic cancer	0.000101	0.00032	CcSEcCtD
Scopolamine—Dysuria—Doxorubicin—hematologic cancer	0.000101	0.000319	CcSEcCtD
Scopolamine—Rash—Thalidomide—hematologic cancer	0.0001	0.000318	CcSEcCtD
Scopolamine—Dermatitis—Thalidomide—hematologic cancer	0.0001	0.000318	CcSEcCtD
Scopolamine—Dizziness—Alitretinoin—hematologic cancer	0.0001	0.000317	CcSEcCtD
Scopolamine—Headache—Thalidomide—hematologic cancer	9.96e-05	0.000316	CcSEcCtD
Scopolamine—Pain—Prednisolone—hematologic cancer	9.96e-05	0.000316	CcSEcCtD
Scopolamine—Sweating—Epirubicin—hematologic cancer	9.95e-05	0.000316	CcSEcCtD
Scopolamine—Asthenia—Gemcitabine—hematologic cancer	9.93e-05	0.000315	CcSEcCtD
Scopolamine—Dizziness—Ifosfamide—hematologic cancer	9.89e-05	0.000314	CcSEcCtD
Scopolamine—Pharyngitis—Methotrexate—hematologic cancer	9.88e-05	0.000313	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—hematologic cancer	9.84e-05	0.000312	CcSEcCtD
Scopolamine—Pruritus—Gemcitabine—hematologic cancer	9.79e-05	0.00031	CcSEcCtD
Scopolamine—Vision blurred—Prednisone—hematologic cancer	9.78e-05	0.00031	CcSEcCtD
Scopolamine—Nausea—Thiotepa—hematologic cancer	9.77e-05	0.00031	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—hematologic cancer	9.76e-05	0.000309	CcSEcCtD
Scopolamine—Feeling abnormal—Etoposide—hematologic cancer	9.73e-05	0.000309	CcSEcCtD
Scopolamine—Oedema—Dexamethasone—hematologic cancer	9.72e-05	0.000308	CcSEcCtD
Scopolamine—Oedema—Betamethasone—hematologic cancer	9.72e-05	0.000308	CcSEcCtD
Scopolamine—Vomiting—Carmustine—hematologic cancer	9.71e-05	0.000308	CcSEcCtD
Scopolamine—Dizziness—Vincristine—hematologic cancer	9.64e-05	0.000306	CcSEcCtD
Scopolamine—Rash—Carmustine—hematologic cancer	9.63e-05	0.000305	CcSEcCtD
Scopolamine—Dermatitis—Carmustine—hematologic cancer	9.62e-05	0.000305	CcSEcCtD
Scopolamine—Vomiting—Alitretinoin—hematologic cancer	9.62e-05	0.000305	CcSEcCtD
Scopolamine—Drowsiness—Doxorubicin—hematologic cancer	9.61e-05	0.000305	CcSEcCtD
Scopolamine—Feeling abnormal—Prednisolone—hematologic cancer	9.6e-05	0.000304	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—hematologic cancer	9.6e-05	0.000304	CcSEcCtD
Scopolamine—Headache—Carmustine—hematologic cancer	9.57e-05	0.000303	CcSEcCtD
Scopolamine—Rash—Alitretinoin—hematologic cancer	9.54e-05	0.000302	CcSEcCtD
Scopolamine—Nervous system disorder—Betamethasone—hematologic cancer	9.53e-05	0.000302	CcSEcCtD
Scopolamine—Nervous system disorder—Dexamethasone—hematologic cancer	9.53e-05	0.000302	CcSEcCtD
Scopolamine—Agitation—Prednisone—hematologic cancer	9.53e-05	0.000302	CcSEcCtD
Scopolamine—Dermatitis—Alitretinoin—hematologic cancer	9.53e-05	0.000302	CcSEcCtD
Scopolamine—Vomiting—Ifosfamide—hematologic cancer	9.51e-05	0.000301	CcSEcCtD
Scopolamine—Tachycardia—Betamethasone—hematologic cancer	9.49e-05	0.000301	CcSEcCtD
Scopolamine—Tachycardia—Dexamethasone—hematologic cancer	9.49e-05	0.000301	CcSEcCtD
Scopolamine—Bradycardia—Epirubicin—hematologic cancer	9.49e-05	0.000301	CcSEcCtD
Scopolamine—Headache—Alitretinoin—hematologic cancer	9.48e-05	0.000301	CcSEcCtD
Scopolamine—Nausea—Thalidomide—hematologic cancer	9.45e-05	0.000299	CcSEcCtD
Scopolamine—Rash—Ifosfamide—hematologic cancer	9.43e-05	0.000299	CcSEcCtD
Scopolamine—Dermatitis—Ifosfamide—hematologic cancer	9.42e-05	0.000299	CcSEcCtD
Scopolamine—Hyperhidrosis—Dexamethasone—hematologic cancer	9.4e-05	0.000298	CcSEcCtD
Scopolamine—Hyperhidrosis—Betamethasone—hematologic cancer	9.4e-05	0.000298	CcSEcCtD
Scopolamine—Dizziness—Irinotecan—hematologic cancer	9.39e-05	0.000298	CcSEcCtD
Scopolamine—Body temperature increased—Etoposide—hematologic cancer	9.34e-05	0.000296	CcSEcCtD
Scopolamine—Abdominal pain—Etoposide—hematologic cancer	9.34e-05	0.000296	CcSEcCtD
Scopolamine—Conjunctivitis—Doxorubicin—hematologic cancer	9.34e-05	0.000296	CcSEcCtD
Scopolamine—Vertigo—Prednisone—hematologic cancer	9.32e-05	0.000295	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—hematologic cancer	9.31e-05	0.000295	CcSEcCtD
Scopolamine—Vomiting—Vincristine—hematologic cancer	9.27e-05	0.000294	CcSEcCtD
Scopolamine—Asthenia—Cisplatin—hematologic cancer	9.25e-05	0.000293	CcSEcCtD
Scopolamine—Pharyngitis—Epirubicin—hematologic cancer	9.25e-05	0.000293	CcSEcCtD
Scopolamine—Fatigue—Triamcinolone—hematologic cancer	9.24e-05	0.000293	CcSEcCtD
Scopolamine—Sweating—Doxorubicin—hematologic cancer	9.21e-05	0.000292	CcSEcCtD
Scopolamine—Urinary tract disorder—Epirubicin—hematologic cancer	9.2e-05	0.000292	CcSEcCtD
Scopolamine—Rash—Vincristine—hematologic cancer	9.19e-05	0.000291	CcSEcCtD
Scopolamine—Dermatitis—Vincristine—hematologic cancer	9.19e-05	0.000291	CcSEcCtD
Scopolamine—Pain—Triamcinolone—hematologic cancer	9.16e-05	0.00029	CcSEcCtD
Scopolamine—Urethral disorder—Epirubicin—hematologic cancer	9.14e-05	0.00029	CcSEcCtD
Scopolamine—Headache—Vincristine—hematologic cancer	9.14e-05	0.00029	CcSEcCtD
Scopolamine—Hypotension—Betamethasone—hematologic cancer	9.08e-05	0.000288	CcSEcCtD
Scopolamine—Hypotension—Dexamethasone—hematologic cancer	9.08e-05	0.000288	CcSEcCtD
Scopolamine—Nausea—Carmustine—hematologic cancer	9.07e-05	0.000288	CcSEcCtD
Scopolamine—Vomiting—Irinotecan—hematologic cancer	9.03e-05	0.000286	CcSEcCtD
Scopolamine—Vomiting—Mitoxantrone—hematologic cancer	9.03e-05	0.000286	CcSEcCtD
Scopolamine—Nausea—Alitretinoin—hematologic cancer	8.99e-05	0.000285	CcSEcCtD
Scopolamine—Visual impairment—Epirubicin—hematologic cancer	8.98e-05	0.000285	CcSEcCtD
Scopolamine—Rash—Mitoxantrone—hematologic cancer	8.95e-05	0.000284	CcSEcCtD
Scopolamine—Rash—Irinotecan—hematologic cancer	8.95e-05	0.000284	CcSEcCtD
Scopolamine—Dermatitis—Irinotecan—hematologic cancer	8.95e-05	0.000284	CcSEcCtD
Scopolamine—Dermatitis—Mitoxantrone—hematologic cancer	8.95e-05	0.000284	CcSEcCtD
Scopolamine—Headache—Irinotecan—hematologic cancer	8.9e-05	0.000282	CcSEcCtD
Scopolamine—Headache—Mitoxantrone—hematologic cancer	8.9e-05	0.000282	CcSEcCtD
Scopolamine—Nausea—Ifosfamide—hematologic cancer	8.88e-05	0.000282	CcSEcCtD
Scopolamine—Feeling abnormal—Triamcinolone—hematologic cancer	8.83e-05	0.00028	CcSEcCtD
Scopolamine—Vomiting—Gemcitabine—hematologic cancer	8.8e-05	0.000279	CcSEcCtD
Scopolamine—Bradycardia—Doxorubicin—hematologic cancer	8.78e-05	0.000278	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.77e-05	0.000278	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—hematologic cancer	8.73e-05	0.000277	CcSEcCtD
Scopolamine—Rash—Gemcitabine—hematologic cancer	8.72e-05	0.000276	CcSEcCtD
Scopolamine—Dermatitis—Gemcitabine—hematologic cancer	8.71e-05	0.000276	CcSEcCtD
Scopolamine—Eye disorder—Epirubicin—hematologic cancer	8.71e-05	0.000276	CcSEcCtD
Scopolamine—Erythema—Methotrexate—hematologic cancer	8.67e-05	0.000275	CcSEcCtD
Scopolamine—Headache—Gemcitabine—hematologic cancer	8.67e-05	0.000275	CcSEcCtD
Scopolamine—Nausea—Vincristine—hematologic cancer	8.66e-05	0.000275	CcSEcCtD
Scopolamine—Flushing—Epirubicin—hematologic cancer	8.65e-05	0.000274	CcSEcCtD
Scopolamine—Pharyngitis—Doxorubicin—hematologic cancer	8.56e-05	0.000271	CcSEcCtD
Scopolamine—Urinary tract disorder—Doxorubicin—hematologic cancer	8.52e-05	0.00027	CcSEcCtD
Scopolamine—Asthenia—Etoposide—hematologic cancer	8.48e-05	0.000269	CcSEcCtD
Scopolamine—Body temperature increased—Triamcinolone—hematologic cancer	8.47e-05	0.000268	CcSEcCtD
Scopolamine—Oedema—Prednisone—hematologic cancer	8.47e-05	0.000268	CcSEcCtD
Scopolamine—Urethral disorder—Doxorubicin—hematologic cancer	8.45e-05	0.000268	CcSEcCtD
Scopolamine—Nausea—Mitoxantrone—hematologic cancer	8.44e-05	0.000267	CcSEcCtD
Scopolamine—Nausea—Irinotecan—hematologic cancer	8.44e-05	0.000267	CcSEcCtD
Scopolamine—Fatigue—Betamethasone—hematologic cancer	8.38e-05	0.000266	CcSEcCtD
Scopolamine—Fatigue—Dexamethasone—hematologic cancer	8.38e-05	0.000266	CcSEcCtD
Scopolamine—Pruritus—Etoposide—hematologic cancer	8.36e-05	0.000265	CcSEcCtD
Scopolamine—Arrhythmia—Epirubicin—hematologic cancer	8.33e-05	0.000264	CcSEcCtD
Scopolamine—Pain—Dexamethasone—hematologic cancer	8.31e-05	0.000264	CcSEcCtD
Scopolamine—Pain—Betamethasone—hematologic cancer	8.31e-05	0.000264	CcSEcCtD
Scopolamine—Visual impairment—Doxorubicin—hematologic cancer	8.31e-05	0.000263	CcSEcCtD
Scopolamine—Nervous system disorder—Prednisone—hematologic cancer	8.3e-05	0.000263	CcSEcCtD
Scopolamine—Tachycardia—Prednisone—hematologic cancer	8.26e-05	0.000262	CcSEcCtD
Scopolamine—Skin disorder—Prednisone—hematologic cancer	8.22e-05	0.000261	CcSEcCtD
Scopolamine—Nausea—Gemcitabine—hematologic cancer	8.22e-05	0.00026	CcSEcCtD
Scopolamine—Vomiting—Cisplatin—hematologic cancer	8.2e-05	0.00026	CcSEcCtD
Scopolamine—Hyperhidrosis—Prednisone—hematologic cancer	8.18e-05	0.000259	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—hematologic cancer	8.17e-05	0.000259	CcSEcCtD
Scopolamine—Mental disorder—Epirubicin—hematologic cancer	8.17e-05	0.000259	CcSEcCtD
Scopolamine—Rash—Cisplatin—hematologic cancer	8.13e-05	0.000258	CcSEcCtD
Scopolamine—Dermatitis—Cisplatin—hematologic cancer	8.12e-05	0.000257	CcSEcCtD
Scopolamine—Erythema—Epirubicin—hematologic cancer	8.11e-05	0.000257	CcSEcCtD
Scopolamine—Eye disorder—Doxorubicin—hematologic cancer	8.06e-05	0.000255	CcSEcCtD
Scopolamine—Feeling abnormal—Betamethasone—hematologic cancer	8.01e-05	0.000254	CcSEcCtD
Scopolamine—Feeling abnormal—Dexamethasone—hematologic cancer	8.01e-05	0.000254	CcSEcCtD
Scopolamine—Flushing—Doxorubicin—hematologic cancer	8e-05	0.000254	CcSEcCtD
Scopolamine—Dizziness—Etoposide—hematologic cancer	7.81e-05	0.000248	CcSEcCtD
Scopolamine—Vertigo—Methotrexate—hematologic cancer	7.79e-05	0.000247	CcSEcCtD
Scopolamine—Dizziness—Prednisolone—hematologic cancer	7.7e-05	0.000244	CcSEcCtD
Scopolamine—Arrhythmia—Doxorubicin—hematologic cancer	7.7e-05	0.000244	CcSEcCtD
Scopolamine—Asthenia—Triamcinolone—hematologic cancer	7.69e-05	0.000244	CcSEcCtD
Scopolamine—Abdominal pain—Dexamethasone—hematologic cancer	7.69e-05	0.000244	CcSEcCtD
Scopolamine—Abdominal pain—Betamethasone—hematologic cancer	7.69e-05	0.000244	CcSEcCtD
Scopolamine—Body temperature increased—Betamethasone—hematologic cancer	7.69e-05	0.000244	CcSEcCtD
Scopolamine—Body temperature increased—Dexamethasone—hematologic cancer	7.69e-05	0.000244	CcSEcCtD
Scopolamine—Nausea—Cisplatin—hematologic cancer	7.66e-05	0.000243	CcSEcCtD
Scopolamine—Vision blurred—Epirubicin—hematologic cancer	7.65e-05	0.000242	CcSEcCtD
Scopolamine—Pruritus—Triamcinolone—hematologic cancer	7.58e-05	0.00024	CcSEcCtD
Scopolamine—Mental disorder—Doxorubicin—hematologic cancer	7.56e-05	0.000239	CcSEcCtD
Scopolamine—Vomiting—Etoposide—hematologic cancer	7.51e-05	0.000238	CcSEcCtD
Scopolamine—Erythema—Doxorubicin—hematologic cancer	7.51e-05	0.000238	CcSEcCtD
Scopolamine—Agitation—Epirubicin—hematologic cancer	7.46e-05	0.000236	CcSEcCtD
Scopolamine—Rash—Etoposide—hematologic cancer	7.45e-05	0.000236	CcSEcCtD
Scopolamine—Dermatitis—Etoposide—hematologic cancer	7.44e-05	0.000236	CcSEcCtD
Scopolamine—Headache—Etoposide—hematologic cancer	7.4e-05	0.000235	CcSEcCtD
Scopolamine—Rash—Prednisolone—hematologic cancer	7.35e-05	0.000233	CcSEcCtD
Scopolamine—Dermatitis—Prednisolone—hematologic cancer	7.34e-05	0.000233	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.33e-05	0.000232	CcSEcCtD
Scopolamine—Fatigue—Prednisone—hematologic cancer	7.3e-05	0.000231	CcSEcCtD
Scopolamine—Headache—Prednisolone—hematologic cancer	7.3e-05	0.000231	CcSEcCtD
Scopolamine—Vertigo—Epirubicin—hematologic cancer	7.29e-05	0.000231	CcSEcCtD
Scopolamine—Constipation—Prednisone—hematologic cancer	7.24e-05	0.00023	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—hematologic cancer	7.13e-05	0.000226	CcSEcCtD
Scopolamine—Dizziness—Triamcinolone—hematologic cancer	7.09e-05	0.000225	CcSEcCtD
Scopolamine—Vision blurred—Doxorubicin—hematologic cancer	7.08e-05	0.000224	CcSEcCtD
Scopolamine—Nausea—Etoposide—hematologic cancer	7.02e-05	0.000222	CcSEcCtD
Scopolamine—Feeling abnormal—Prednisone—hematologic cancer	6.98e-05	0.000221	CcSEcCtD
Scopolamine—Asthenia—Dexamethasone—hematologic cancer	6.98e-05	0.000221	CcSEcCtD
Scopolamine—Asthenia—Betamethasone—hematologic cancer	6.98e-05	0.000221	CcSEcCtD
Scopolamine—Nervous system disorder—Methotrexate—hematologic cancer	6.94e-05	0.00022	CcSEcCtD
Scopolamine—Nausea—Prednisolone—hematologic cancer	6.92e-05	0.000219	CcSEcCtD
Scopolamine—Agitation—Doxorubicin—hematologic cancer	6.9e-05	0.000219	CcSEcCtD
Scopolamine—Pruritus—Betamethasone—hematologic cancer	6.88e-05	0.000218	CcSEcCtD
Scopolamine—Pruritus—Dexamethasone—hematologic cancer	6.88e-05	0.000218	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—hematologic cancer	6.87e-05	0.000218	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.86e-05	0.000217	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—hematologic cancer	6.84e-05	0.000217	CcSEcCtD
Scopolamine—Vomiting—Triamcinolone—hematologic cancer	6.81e-05	0.000216	CcSEcCtD
Scopolamine—Rash—Triamcinolone—hematologic cancer	6.76e-05	0.000214	CcSEcCtD
Scopolamine—Dry mouth—Epirubicin—hematologic cancer	6.76e-05	0.000214	CcSEcCtD
Scopolamine—Dermatitis—Triamcinolone—hematologic cancer	6.75e-05	0.000214	CcSEcCtD
Scopolamine—Vertigo—Doxorubicin—hematologic cancer	6.74e-05	0.000214	CcSEcCtD
Scopolamine—Headache—Triamcinolone—hematologic cancer	6.71e-05	0.000213	CcSEcCtD
Scopolamine—Body temperature increased—Prednisone—hematologic cancer	6.69e-05	0.000212	CcSEcCtD
Scopolamine—Abdominal pain—Prednisone—hematologic cancer	6.69e-05	0.000212	CcSEcCtD
Scopolamine—Confusional state—Epirubicin—hematologic cancer	6.68e-05	0.000212	CcSEcCtD
Scopolamine—Oedema—Epirubicin—hematologic cancer	6.62e-05	0.00021	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—hematologic cancer	6.61e-05	0.00021	CcSEcCtD
Scopolamine—Nervous system disorder—Epirubicin—hematologic cancer	6.49e-05	0.000206	CcSEcCtD
Scopolamine—Tachycardia—Epirubicin—hematologic cancer	6.46e-05	0.000205	CcSEcCtD
Scopolamine—Skin disorder—Epirubicin—hematologic cancer	6.43e-05	0.000204	CcSEcCtD
Scopolamine—Dizziness—Betamethasone—hematologic cancer	6.43e-05	0.000204	CcSEcCtD
Scopolamine—Dizziness—Dexamethasone—hematologic cancer	6.43e-05	0.000204	CcSEcCtD
Scopolamine—Hyperhidrosis—Epirubicin—hematologic cancer	6.4e-05	0.000203	CcSEcCtD
Scopolamine—Nausea—Triamcinolone—hematologic cancer	6.36e-05	0.000202	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.35e-05	0.000201	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—hematologic cancer	6.29e-05	0.000199	CcSEcCtD
Scopolamine—Dry mouth—Doxorubicin—hematologic cancer	6.25e-05	0.000198	CcSEcCtD
Scopolamine—Hypotension—Epirubicin—hematologic cancer	6.19e-05	0.000196	CcSEcCtD
Scopolamine—Vomiting—Betamethasone—hematologic cancer	6.18e-05	0.000196	CcSEcCtD
Scopolamine—Vomiting—Dexamethasone—hematologic cancer	6.18e-05	0.000196	CcSEcCtD
Scopolamine—Confusional state—Doxorubicin—hematologic cancer	6.18e-05	0.000196	CcSEcCtD
Scopolamine—Rash—Dexamethasone—hematologic cancer	6.13e-05	0.000194	CcSEcCtD
Scopolamine—Rash—Betamethasone—hematologic cancer	6.13e-05	0.000194	CcSEcCtD
Scopolamine—Oedema—Doxorubicin—hematologic cancer	6.13e-05	0.000194	CcSEcCtD
Scopolamine—Dermatitis—Betamethasone—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Scopolamine—Dermatitis—Dexamethasone—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—hematologic cancer	6.1e-05	0.000193	CcSEcCtD
Scopolamine—Headache—Betamethasone—hematologic cancer	6.09e-05	0.000193	CcSEcCtD
Scopolamine—Headache—Dexamethasone—hematologic cancer	6.09e-05	0.000193	CcSEcCtD
Scopolamine—Asthenia—Prednisone—hematologic cancer	6.07e-05	0.000193	CcSEcCtD
Scopolamine—Pain—Methotrexate—hematologic cancer	6.05e-05	0.000192	CcSEcCtD
Scopolamine—Nervous system disorder—Doxorubicin—hematologic cancer	6.01e-05	0.00019	CcSEcCtD
Scopolamine—Pruritus—Prednisone—hematologic cancer	5.99e-05	0.00019	CcSEcCtD
Scopolamine—Tachycardia—Doxorubicin—hematologic cancer	5.98e-05	0.00019	CcSEcCtD
Scopolamine—Skin disorder—Doxorubicin—hematologic cancer	5.95e-05	0.000189	CcSEcCtD
Scopolamine—Hyperhidrosis—Doxorubicin—hematologic cancer	5.92e-05	0.000188	CcSEcCtD
Scopolamine—Somnolence—Epirubicin—hematologic cancer	5.89e-05	0.000187	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—hematologic cancer	5.83e-05	0.000185	CcSEcCtD
Scopolamine—Nausea—Betamethasone—hematologic cancer	5.77e-05	0.000183	CcSEcCtD
Scopolamine—Nausea—Dexamethasone—hematologic cancer	5.77e-05	0.000183	CcSEcCtD
Scopolamine—Hypotension—Doxorubicin—hematologic cancer	5.73e-05	0.000181	CcSEcCtD
Scopolamine—Fatigue—Epirubicin—hematologic cancer	5.71e-05	0.000181	CcSEcCtD
Scopolamine—Pain—Epirubicin—hematologic cancer	5.66e-05	0.000179	CcSEcCtD
Scopolamine—Constipation—Epirubicin—hematologic cancer	5.66e-05	0.000179	CcSEcCtD
Scopolamine—Dizziness—Prednisone—hematologic cancer	5.6e-05	0.000177	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—hematologic cancer	5.59e-05	0.000177	CcSEcCtD
Scopolamine—Abdominal pain—Methotrexate—hematologic cancer	5.59e-05	0.000177	CcSEcCtD
Scopolamine—Feeling abnormal—Epirubicin—hematologic cancer	5.46e-05	0.000173	CcSEcCtD
Scopolamine—Somnolence—Doxorubicin—hematologic cancer	5.45e-05	0.000173	CcSEcCtD
Scopolamine—Vomiting—Prednisone—hematologic cancer	5.38e-05	0.000171	CcSEcCtD
Scopolamine—Rash—Prednisone—hematologic cancer	5.34e-05	0.000169	CcSEcCtD
Scopolamine—Dermatitis—Prednisone—hematologic cancer	5.33e-05	0.000169	CcSEcCtD
Scopolamine—Headache—Prednisone—hematologic cancer	5.3e-05	0.000168	CcSEcCtD
Scopolamine—Fatigue—Doxorubicin—hematologic cancer	5.28e-05	0.000167	CcSEcCtD
Scopolamine—Constipation—Doxorubicin—hematologic cancer	5.24e-05	0.000166	CcSEcCtD
Scopolamine—Pain—Doxorubicin—hematologic cancer	5.24e-05	0.000166	CcSEcCtD
Scopolamine—Body temperature increased—Epirubicin—hematologic cancer	5.23e-05	0.000166	CcSEcCtD
Scopolamine—Abdominal pain—Epirubicin—hematologic cancer	5.23e-05	0.000166	CcSEcCtD
Scopolamine—Asthenia—Methotrexate—hematologic cancer	5.08e-05	0.000161	CcSEcCtD
Scopolamine—Feeling abnormal—Doxorubicin—hematologic cancer	5.05e-05	0.00016	CcSEcCtD
Scopolamine—Nausea—Prednisone—hematologic cancer	5.03e-05	0.000159	CcSEcCtD
Scopolamine—Pruritus—Methotrexate—hematologic cancer	5.01e-05	0.000159	CcSEcCtD
Scopolamine—Body temperature increased—Doxorubicin—hematologic cancer	4.84e-05	0.000154	CcSEcCtD
Scopolamine—Abdominal pain—Doxorubicin—hematologic cancer	4.84e-05	0.000154	CcSEcCtD
Scopolamine—Asthenia—Epirubicin—hematologic cancer	4.75e-05	0.000151	CcSEcCtD
Scopolamine—Pruritus—Epirubicin—hematologic cancer	4.68e-05	0.000149	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—hematologic cancer	4.68e-05	0.000148	CcSEcCtD
Scopolamine—Vomiting—Methotrexate—hematologic cancer	4.5e-05	0.000143	CcSEcCtD
Scopolamine—Rash—Methotrexate—hematologic cancer	4.46e-05	0.000141	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—hematologic cancer	4.46e-05	0.000141	CcSEcCtD
Scopolamine—Headache—Methotrexate—hematologic cancer	4.43e-05	0.000141	CcSEcCtD
Scopolamine—Asthenia—Doxorubicin—hematologic cancer	4.4e-05	0.000139	CcSEcCtD
Scopolamine—Dizziness—Epirubicin—hematologic cancer	4.38e-05	0.000139	CcSEcCtD
Scopolamine—Pruritus—Doxorubicin—hematologic cancer	4.33e-05	0.000137	CcSEcCtD
Scopolamine—Vomiting—Epirubicin—hematologic cancer	4.21e-05	0.000133	CcSEcCtD
Scopolamine—Nausea—Methotrexate—hematologic cancer	4.2e-05	0.000133	CcSEcCtD
Scopolamine—Rash—Epirubicin—hematologic cancer	4.18e-05	0.000132	CcSEcCtD
Scopolamine—Dermatitis—Epirubicin—hematologic cancer	4.17e-05	0.000132	CcSEcCtD
Scopolamine—Headache—Epirubicin—hematologic cancer	4.15e-05	0.000131	CcSEcCtD
Scopolamine—Dizziness—Doxorubicin—hematologic cancer	4.05e-05	0.000128	CcSEcCtD
Scopolamine—Nausea—Epirubicin—hematologic cancer	3.93e-05	0.000125	CcSEcCtD
Scopolamine—Vomiting—Doxorubicin—hematologic cancer	3.9e-05	0.000123	CcSEcCtD
Scopolamine—Rash—Doxorubicin—hematologic cancer	3.86e-05	0.000122	CcSEcCtD
Scopolamine—Dermatitis—Doxorubicin—hematologic cancer	3.86e-05	0.000122	CcSEcCtD
Scopolamine—Headache—Doxorubicin—hematologic cancer	3.84e-05	0.000122	CcSEcCtD
Scopolamine—Nausea—Doxorubicin—hematologic cancer	3.64e-05	0.000115	CcSEcCtD
Scopolamine—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	7.96e-06	6.57e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MTOR—hematologic cancer	7.91e-06	6.53e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CB—hematologic cancer	7.91e-06	6.53e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TSC2—hematologic cancer	7.88e-06	6.5e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TSC2—hematologic cancer	7.85e-06	6.48e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—PIK3CA—hematologic cancer	7.81e-06	6.45e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MDM2—hematologic cancer	7.78e-06	6.42e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TSC2—hematologic cancer	7.78e-06	6.42e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTP1—hematologic cancer	7.71e-06	6.37e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CREBBP—hematologic cancer	7.69e-06	6.35e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	7.58e-06	6.25e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CB—hematologic cancer	7.57e-06	6.25e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MTOR—hematologic cancer	7.57e-06	6.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	7.55e-06	6.23e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—HRAS—hematologic cancer	7.55e-06	6.23e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	7.5e-06	6.19e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	7.48e-06	6.17e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	7.48e-06	6.17e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1B—hematologic cancer	7.42e-06	6.12e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	7.41e-06	6.11e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ESR1—hematologic cancer	7.36e-06	6.07e-05	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—AKT1—hematologic cancer	7.34e-06	6.06e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ESR1—hematologic cancer	7.34e-06	6.05e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CD—hematologic cancer	7.29e-06	6.02e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CASP3—hematologic cancer	7.27e-06	6e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FN1—hematologic cancer	7.27e-06	6e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ESR1—hematologic cancer	7.27e-06	6e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL2—hematologic cancer	7.26e-06	5.99e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FN1—hematologic cancer	7.25e-06	5.98e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	7.23e-06	5.97e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL6—hematologic cancer	7.23e-06	5.96e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ALB—hematologic cancer	7.2e-06	5.94e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BAD—hematologic cancer	7.18e-06	5.93e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	7.18e-06	5.93e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FN1—hematologic cancer	7.18e-06	5.92e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	7.16e-06	5.91e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BAD—hematologic cancer	7.16e-06	5.91e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	7.12e-06	5.87e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	7.11e-06	5.86e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	7.09e-06	5.85e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BAD—hematologic cancer	7.09e-06	5.85e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	7.09e-06	5.85e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTM1—hematologic cancer	7.09e-06	5.85e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—NCOR1—hematologic cancer	7.09e-06	5.85e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCND1—hematologic cancer	7.08e-06	5.84e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—JUN—hematologic cancer	7.06e-06	5.83e-05	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	7.03e-06	5.8e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	7.02e-06	5.8e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CD80—hematologic cancer	6.97e-06	5.75e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CASP3—hematologic cancer	6.96e-06	5.75e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KIT—hematologic cancer	6.96e-06	5.74e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	6.96e-06	5.74e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	6.96e-06	5.74e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL2—hematologic cancer	6.95e-06	5.74e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CD80—hematologic cancer	6.95e-06	5.73e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	6.94e-06	5.72e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KIT—hematologic cancer	6.94e-06	5.72e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	6.94e-06	5.72e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL6—hematologic cancer	6.92e-06	5.71e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3R1—hematologic cancer	6.89e-06	5.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CD80—hematologic cancer	6.88e-06	5.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	6.87e-06	5.67e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KIT—hematologic cancer	6.87e-06	5.67e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	6.87e-06	5.67e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	6.85e-06	5.65e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	6.84e-06	5.64e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PTEN—hematologic cancer	6.83e-06	5.64e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	6.81e-06	5.62e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCND1—hematologic cancer	6.78e-06	5.59e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—JUN—hematologic cancer	6.76e-06	5.58e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	6.75e-06	5.57e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	6.68e-06	5.52e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	6.67e-06	5.5e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	6.66e-06	5.5e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	6.64e-06	5.48e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	6.62e-06	5.47e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CREB1—hematologic cancer	6.6e-06	5.45e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	6.58e-06	5.43e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	6.56e-06	5.41e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PTEN—hematologic cancer	6.54e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	6.54e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CREB1—hematologic cancer	6.54e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	6.52e-06	5.38e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EP300—hematologic cancer	6.52e-06	5.38e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	6.48e-06	5.35e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	6.46e-06	5.33e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	6.46e-06	5.33e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	6.46e-06	5.33e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	6.45e-06	5.32e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	6.44e-06	5.31e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	6.43e-06	5.31e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	6.4e-06	5.28e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	6.4e-06	5.28e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	6.38e-06	5.27e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	6.38e-06	5.26e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	6.37e-06	5.26e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CB—hematologic cancer	6.36e-06	5.25e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SRC—hematologic cancer	6.34e-06	5.23e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—MTHFR—hematologic cancer	6.26e-06	5.17e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EP300—hematologic cancer	6.24e-06	5.15e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	6.17e-06	5.09e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	6.16e-06	5.08e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	6.14e-06	5.06e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	6.12e-06	5.05e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—STAT3—hematologic cancer	6.11e-06	5.04e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	6.1e-06	5.03e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—NRAS—hematologic cancer	6.1e-06	5.03e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	6.08e-06	5.02e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SRC—hematologic cancer	6.07e-06	5.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.06e-06	5e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	6.04e-06	4.98e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	6.04e-06	4.98e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	5.99e-06	4.94e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	5.98e-06	4.94e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	5.97e-06	4.93e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	5.91e-06	4.88e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	5.91e-06	4.88e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	5.86e-06	4.83e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—STAT3—hematologic cancer	5.85e-06	4.83e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	5.84e-06	4.82e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	5.84e-06	4.82e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—NRAS—hematologic cancer	5.84e-06	4.82e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	5.78e-06	4.77e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	5.78e-06	4.77e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	5.76e-06	4.75e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	5.7e-06	4.71e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MYC—hematologic cancer	5.68e-06	4.69e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	5.66e-06	4.67e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	5.61e-06	4.63e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	5.6e-06	4.62e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	5.59e-06	4.61e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	5.54e-06	4.57e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	5.5e-06	4.54e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTEN—hematologic cancer	5.49e-06	4.53e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	5.48e-06	4.53e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	5.48e-06	4.52e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	5.46e-06	4.51e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MYC—hematologic cancer	5.44e-06	4.49e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	5.43e-06	4.48e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	5.42e-06	4.48e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	5.41e-06	4.46e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	5.33e-06	4.4e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	5.33e-06	4.4e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	5.31e-06	4.39e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	5.31e-06	4.39e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CG—hematologic cancer	5.26e-06	4.34e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	5.26e-06	4.34e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	5.26e-06	4.34e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KRAS—hematologic cancer	5.25e-06	4.33e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—EP300—hematologic cancer	5.24e-06	4.32e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	5.09e-06	4.2e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	5.07e-06	4.19e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	5.02e-06	4.15e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KRAS—hematologic cancer	5.02e-06	4.15e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	5e-06	4.13e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	4.99e-06	4.12e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	4.95e-06	4.08e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	4.94e-06	4.08e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	4.93e-06	4.07e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	4.9e-06	4.05e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL2—hematologic cancer	4.9e-06	4.04e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	4.89e-06	4.03e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	4.89e-06	4.03e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL2—hematologic cancer	4.88e-06	4.03e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CREBBP—hematologic cancer	4.88e-06	4.03e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	4.87e-06	4.02e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	4.86e-06	4.01e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	4.84e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL2—hematologic cancer	4.83e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	4.82e-06	3.98e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	4.81e-06	3.97e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	4.77e-06	3.94e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JUN—hematologic cancer	4.76e-06	3.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	4.76e-06	3.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JUN—hematologic cancer	4.75e-06	3.92e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	4.71e-06	3.89e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JUN—hematologic cancer	4.7e-06	3.88e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TP53—hematologic cancer	4.66e-06	3.85e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CD—hematologic cancer	4.63e-06	3.82e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	4.62e-06	3.81e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	4.62e-06	3.81e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	4.61e-06	3.8e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	4.6e-06	3.8e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	4.59e-06	3.79e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ALB—hematologic cancer	4.57e-06	3.77e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	4.56e-06	3.76e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	4.55e-06	3.75e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	4.51e-06	3.72e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	4.49e-06	3.71e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	4.49e-06	3.71e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	4.48e-06	3.7e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TP53—hematologic cancer	4.47e-06	3.69e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	4.46e-06	3.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	4.45e-06	3.67e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	4.44e-06	3.66e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EP300—hematologic cancer	4.39e-06	3.63e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EP300—hematologic cancer	4.38e-06	3.61e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3R1—hematologic cancer	4.37e-06	3.61e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EP300—hematologic cancer	4.34e-06	3.58e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SRC—hematologic cancer	4.27e-06	3.53e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	4.27e-06	3.52e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL6—hematologic cancer	4.27e-06	3.52e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SRC—hematologic cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SRC—hematologic cancer	4.22e-06	3.48e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	4.16e-06	3.43e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	4.15e-06	3.42e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	4.12e-06	3.4e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	4.11e-06	3.39e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	4.11e-06	3.39e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	4.11e-06	3.39e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	4.1e-06	3.38e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL6—hematologic cancer	4.09e-06	3.37e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	4.07e-06	3.36e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	4.06e-06	3.35e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CB—hematologic cancer	4.03e-06	3.33e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	3.94e-06	3.25e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	3.94e-06	3.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	3.92e-06	3.24e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	3.89e-06	3.21e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CA—hematologic cancer	3.87e-06	3.2e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MYC—hematologic cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	3.82e-06	3.15e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MYC—hematologic cancer	3.82e-06	3.15e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	3.81e-06	3.14e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MYC—hematologic cancer	3.78e-06	3.12e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	3.77e-06	3.11e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	3.77e-06	3.11e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	3.54e-06	2.92e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	3.53e-06	2.91e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	3.49e-06	2.88e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTEN—hematologic cancer	3.48e-06	2.88e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—EP300—hematologic cancer	3.32e-06	2.74e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	3.25e-06	2.68e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	3.24e-06	2.67e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	3.21e-06	2.65e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AKT1—hematologic cancer	3.17e-06	2.61e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TP53—hematologic cancer	3.14e-06	2.59e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TP53—hematologic cancer	3.13e-06	2.59e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TP53—hematologic cancer	3.1e-06	2.56e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	3.01e-06	2.48e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	3e-06	2.47e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.97e-06	2.45e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6—hematologic cancer	2.88e-06	2.37e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6—hematologic cancer	2.87e-06	2.37e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6—hematologic cancer	2.84e-06	2.34e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	2.66e-06	2.19e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	2.65e-06	2.18e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	2.62e-06	2.16e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.46e-06	2.03e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AKT1—hematologic cancer	2.01e-06	1.66e-05	CbGpPWpGaD
